Evidence map›Paper›PMID 39347707›Full record

ReviewOncotarget2024

Linking FOXM1 and PD-L1 to CDK4/6-MEK targeted therapy resistance in malignant peripheral nerve sheath tumors.

Joshua J Lingo, Ellen Voigt, Dawn E Quelle

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncotarget, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Joshua J LingoCancer Biology Graduate Program, University of Iowa, Iowa City, IA 52242, USA.
Ellen VoigtCancer Biology Graduate Program, University of Iowa, Iowa City, IA 52242, USA.
Dawn E QuelleCancer Biology Graduate Program, University of Iowa, Iowa City, IA 52242, USA.

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Jon C.D. Houtman · 2000 to 2026
$70.0M
Medical Scientist Training ProgramT32GM139776 · NIGMS · UNIVERSITY OF IOWA · PI Gordon F Buchanan · 2021 to 2026
$6.4M
Ink4a/ARF/Ink4b locus in Neurofibromatosis Type 1R01NS119322 · NINDS · UNIVERSITY OF IOWA · PI Benjamin Will Darbro, Rebecca D Dodd · 2022 to 2026
$2.6M
Intratumoral plasma cells in MPNST response to CDK4/6 targeted therapy and sensitization to immune checkpoint blockadeF31CA281312 · NCI · UNIVERSITY OF IOWA · PI LINGO, JOSHUA J · 2023 to 2024
$70k
NCI NIH HHS F31 CA281312NCI NIH HHS P30 CA086862NIGMS NIH HHS T32 GM139776NINDS NIH HHS R01 NS119322
6 · The paper itself

Abstract

Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive, Ras-driven sarcomas characterized by loss of the

Indexed as

B7-H1 AntigenCyclin-Dependent Kinase 4Drug Resistance, NeoplasmForkhead Box Protein M1AnimalsCyclin-Dependent Kinase 6HumansMiceMolecular Targeted TherapyNerve Sheath NeoplasmsNeurofibrosarcomaProtein Kinase InhibitorsB7-H1 AntigenCD274 protein, humanCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Forkhead Box Protein M1FOXM1 protein, humanProtein Kinase InhibitorsCDK4/6-MEK targetingFOXM1MPNSTPD-L1therapy resistance

Identifiers

PMID39347707
PMCPMC11441412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.